This phase II trial studies how well proteasome inhibitor MLN9708 works in treating patients with relapsed multiple myeloma that is not refractory to bortezomib. Proteasome inhibitor MLN9708 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
There are no resources, links or videos to display for this clinical trial.